News

The European Commission’s probe into suspected anti-trust activity in the pharmaceutical sector is rumbling on, with further dawn raids earlier this week.

After resigning as Vice President of Research at ETH Zurich over a case involving falsification of scientific data, Peter Chen says why his resignation “was inevitable”.

A new campaign seeks to persuade regulators to set new rules for approving personalised treatments that are currently in clinical development.

The European Research Area is too fractured and much by inward-looking national priorities, an advisory body warns, urging a fundamental shift in the way research is done.